Last Price$155.4(2.4%)
Market Cap$8,979.7M
LTM Long-Term Investments
$0.0
YoY Growth
N/A
3Y CAGR
N/A
5Y CAGR
N/A
Stock quality & Intrinsic value
6/10
80.8% overvalued
Repligen Corporation Long-Term Investments
Annual
Quarterly
LTM
Crunching data... Almost there!
| Mar'04 | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Investments | $6,630.7M | $6,630.7M | $4,531.5M | $10.8B | $10.8B | $15.1M | $6,011.7K | $11.9M | $9,914.9K | $12.2M | $3,550.2K | $1,633.0K | $450.0K | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $6,471.0K |
Overvalued or undervalued?
Check the intrinsic value for RGEN
and see if it's the right time to invest.
Repligen Corporation (RGEN) Long-Term Investments comparison analysis
General
LTM Long-Term Investments
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Repligen CorporationRGEN
$0.0
N/A
N/A
N/A
Median Peer Set
$28.3M
(23.8%)
(12.8%)
0.5%
Intuitive Surgical, Inc.ISRG
$4,819.1M
127.3%
3.0%
12.9%
Alcon Inc.ALC
$751.0M
174.2%
143.5%
66.3%
West Pharmaceutical Services, Inc.WST
$202.1M
(3.8%)
(0.9%)
1.0%
Baxter International Inc.BAX
$109.0M
(43.8%)
(10.9%)
7.5%
Hologic, Inc.HOLX
$47.9M
N/A
N/A
N/A
Masimo CorporationMASI
$8,600.0K
(92.3%)
(14.6%)
5.8%
Becton, Dickinson and CompanyBDX
$0.0
(100.0%)
(100.0%)
(100.0%)
The Cooper Companies, Inc.COO
$0.0
N/A
(100.0%)
N/A
AptarGroup, Inc.ATR
$0.0
(100.0%)
(100.0%)
(100.0%)
ResMed Inc.RMD
$0.0
(100.0%)
(100.0%)
(100.0%)
RGEN key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Mar'04 | Mar'05 | Mar'06 | Mar'07 | Mar'08 | Mar'09 | Mar'10 | Mar'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 6.9 0.0% | 9.4 35.4% | 12.9 37.9% | 14.1 9.0% | 19.3 37.1% | 29.4 52.2% | 21.0 (28.6%) | 27.3 30.1% | 62.3 128.2% | 68.2 9.5% | 63.5 (6.8%) | 83.5 31.5% | 104.5 25.1% | 141.2 35.1% | 194.0 37.4% | 270.2 39.3% | 366.3 35.5% | 670.5 83.1% | 801.5 19.5% | 632.4 (21.1%) |
| Cost of Goods Sold (COGS) | 3.2 | 3.9 | 3.6 | 3.6 | 6.2 | 6.8 | 5.5 | 7.1 | 27.2 | 25.2 | 28.0 | 35.3 | 47.1 | 67.1 | 86.0 | 119.1 | 156.6 | 279.3 | 345.8 | 323.5 |
% margin | 3.7 53.0% | 5.5 58.5% | 9.4 72.5% | 10.5 74.3% | 13.1 68.1% | 22.6 76.9% | 15.5 73.7% | 20.2 73.9% | 35.1 56.4% | 43.0 63.1% | 35.5 55.9% | 48.3 57.8% | 57.4 54.9% | 74.2 52.5% | 108.1 55.7% | 151.1 55.9% | 209.6 57.2% | 391.3 58.3% | 455.7 56.9% | 308.8 48.8% |
| Operating Expenses | 13.6 | 9.6 | 10.6 | 12.3 | (22.8) | 18.7 | 21.2 | 20.5 | 23.7 | 20.0 | 22.8 | 30.4 | 38.2 | 60.2 | 82.1 | 115.1 | 139.8 | 218.1 | 259.8 | 261.1 |
| Research & Development Expenses (R&D) | 6.5 | 5.0 | 5.2 | 5.9 | 7.2 | 12.8 | 14.2 | 12.5 | 10.5 | 7.3 | 5.6 | 5.7 | 7.4 | 8.7 | 15.8 | 19.5 | 20.2 | 34.3 | 43.9 | 42.7 |
| Selling, General & Administrative Expenses (SG&A) | 4.7 | 4.6 | 5.4 | 6.4 | 10.2 | 5.9 | 7.1 | 8.0 | 13.2 | 12.7 | 17.2 | 24.7 | 30.9 | 51.5 | 66.3 | 95.6 | 119.6 | 183.9 | 215.8 | 216.9 |
% margin | (9.9) (143.8%) | (4.2) (44.5%) | (1.2) (9.4%) | (1.8) (13.0%) | 35.9 186.0% | 3.9 13.2% | (5.8) (27.5%) | (0.4) (1.4%) | 11.1 17.8% | 22.9 33.6% | 10.7 16.8% | 13.8 16.5% | 16.0 15.3% | 14.0 9.9% | 26.0 13.4% | 14.9 5.5% | 42.5 11.6% | 133.5 19.9% | 133.6 16.7% | 47.7 7.5% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.3 | 1.7 | 0.2 | 7.0 | 0.0 |
| Interest Expense | 0.0 | 0.0 | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 3.8 | 6.4 | 6.7 | 9.3 | 12.1 | 12.7 | 1.2 | 10.0 |
| Pre-tax Income | (9.6) | (3.0) | 0.7 | (0.9) | 37.9 | 5.8 | (4.9) | (0.0) | 11.3 | 23.0 | 11.1 | 13.4 | 11.7 | 7.2 | 21.4 | 26.2 | 59.2 | 153.5 | 219.1 | 56.7 |
% effective tax rate | 9.6 (100.0%) | 3.0 (100.0%) | (0.7) (100.0%) | 0.9 (100.0%) | 0.8 2.2% | 0.0 0.5% | (0.8) 17.0% | (0.3) 759.8% | (2.9) (25.6%) | 6.9 30.1% | 3.0 26.6% | 4.1 30.4% | 0.0 0.1% | (21.1) (291.2%) | 4.8 22.5% | 4.7 18.1% | (0.7) (1.2%) | 25.3 16.4% | 33.2 15.1% | 21.1 37.2% |
% margin | (9.6) (138.1%) | (3.0) (31.9%) | 0.7 5.4% | (0.9) (6.3%) | 37.1 192.3% | 5.7 19.6% | (4.1) (19.4%) | (0.0) (0.2%) | 14.2 22.7% | 16.1 23.6% | 8.2 12.9% | 9.3 11.2% | 11.7 11.2% | 28.4 20.1% | 16.6 8.6% | 21.4 7.9% | 59.9 16.4% | 128.3 19.1% | 186.0 23.2% | 35.6 5.6% |
| EPS | (0.32) | (0.10) | 0.02 | (0.03) | 1.20 | 0.19 | (0.13) | (0.00) | 0.46 | 0.51 | 0.25 | 0.28 | 0.35 | 0.74 | 0.38 | 0.44 | 1.14 | 2.33 | 3.35 | 0.64 |
| Diluted EPS | (0.32) | (0.10) | 0.02 | (0.03) | 1.18 | 0.18 | (0.13) | (0.00) | 0.45 | 0.50 | 0.25 | 0.28 | 0.34 | 0.72 | 0.37 | 0.44 | 1.11 | 2.24 | 3.24 | 0.63 |
% margin | (2.2) (32.2%) | (1.2) (13.0%) | (1.8) (14.1%) | 36.7 260.9% | 6.9 35.5% | (3.5) (12.0%) | 1.7 7.9% | (0.0) (0.1%) | 14.8 23.8% | 26.1 38.3% | 15.2 23.9% | 22.4 26.9% | 24.6 23.5% | 24.1 17.1% | 41.8 21.5% | 58.4 21.6% | 101.6 27.7% | 211.6 31.6% | 246.9 30.8% | 127.8 20.2% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Repligen Corporation's Long-Term Investments?
As of today, Repligen Corporation's last 12-month Long-Term Investments is $0.0, based on the financial report for Sep 30, 2024 (Q3’2024).
2) What is Repligen Corporation's Long-Term Investments growth rate?
Over the last year, Repligen Corporation's Long-Term Investments growth was N/A. The average annual Long-Term Investments growth rates for Repligen Corporation have been N/A over the past three years, N/A over the past five years.